For TERAPET, ESTRO 2026 represented far more than a congress participation. It marked our first presence at European Society for Radiation Oncology Annual meeting, the introduction of our newly rebranded identity, and an important opportunity to present our expanding portfolio of technologies to the international radiation oncology community.
Throughout the week in Stockholm, we had the chance to meet clinicians, medical physicists, researchers and industrial partners from all over the world, exchanging ideas around one common objective: bringing more integrated, adaptive and reliable verification workflows into particle therapy.
One of the main highlights of the congress was the opportunity to present, together with Leo Cancer Care and RaySearch Laboratories, our shared vision for upright particle therapy through two dedicated talks:
“From Plan to Proof in Upright Particle Therapy: Integrating Treatment Planning, Upright Delivery and In-Vivo PET Verification”
The presentation was first delivered at the RaySearch booth and later featured on the ESTRO Stage, focusing on the integration of treatment planning, upright treatment delivery and in-vivo PET verification within a single workflow.
At the center of these presentations was Qualyscan Upright®, TERAPET’s concept for in-vivo PET verification in upright particle therapy. Designed to operate directly in treatment position, the system aims to enable PET imaging immediately after irradiation or during arc therapy delivery, supporting the comparison between expected and measured PET activity distributions based on real measurements. The objective is to strengthen treatment verification workflows while supporting future adaptive and replanning strategies.
ESTRO 2026 also represented an important opportunity to present the TERAPET portfolio and discuss future perspectives for clinical integration with companies and institutions across the radiation oncology ecosystem.
As the only company at the congress presenting dedicated solutions specifically focused on PET-based in-vivo verification for particle therapy, the event confirmed the growing interest around technologies capable of helping close the loop between planned and delivered treatment.
Beyond the scientific and technological discussions, ESTRO 2026 was also an important milestone in TERAPET’s evolution as a company, reflecting the transition from a single-product vision toward a broader portfolio of integrated solutions for particle therapy and nuclear medicine.
We would like to sincerely thank everyone who visited us during the congress, all the partners and collaborators supporting TERAPET’s journey, and especially Leo Cancer Care for hosting us throughout this important week.
